CTL-119 is under clinical development by Novartis and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTL-119’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTL-119 overview
CTL-119 (huCTL019) is under development for the treatment of relapsed or refractory acute lymphocytic leukemia (ALL, acute lymphoblastic leukemia), follicular lymphoma, high grade non-Hodgkin lymphoma, diffuse large B-cell lymphoma. The therapeutic candidate is administered intravenously. It is a humanized version of anti-CD19 scFv domain that consists of CARs combined with an antigen recognition domain of anti-CD19 antibody linked to an intracellular domain of the CD28 or CD137 (4-1BB) protein into a single chimeric protein. CART19 cells transduced with a lentiviral vector to express humanized anti-CD19. It is a second generation CAR-T against CD19 and is based on CAR technology. It was under development for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).
Novartis overview
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of CTL-119’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
